Halozyme To Present Data From Five Preclinical Studies At American Association Of Cancer Research Annual Conference

Share This


Abstracts include the first data from two novel Halozyme-developed pipeline assets and continued research on the pan-tumor and pan-therapy potential of lead investigational agent, PEGPH20
Company to host meeting for investment professionals on April 18 at 4:00 p.m. ET

SAN DIEGO, March 17, 2016 /PRNewswire/ -- Halozyme Therapeutics (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, will present preclinical data from five studies at the American Association of Cancer Research (AACR) annual conference next month, including results from its ongoing research of lead investigational agent, PEGPH20, and two novel pipeline assets engineered for increased action in the tumor microenvironment. The AACR annual conference will take place April 17-20 in New Orleans.

The new Halozyme research builds on previously published data demonstrating increased concentration of immune cells, immunotherapies and chemotherapies in animal models when delivered in combination with PEGPH20. The studies that will be presented at AACR show enhanced efficacy of checkpoint inhibitors on tumor growth inhibition when treated with PEGPH20, further expanding the company's growing body of preclinical research supporting PEGPH20's mechanism of action and potential applicability across multiple types of cancer therapy.

In addition, Halozyme will share data from two novel Halozyme-developed pipeline assets, an immune checkpoint inhibitor that targets adenosine in the tumor microenvironment and an anti-EGFR antibody-drug conjugate.

"We are pleased to share the research of our talented scientists to build on our study of novel agents targeting the tumor microenvironment," said Dr. Helen Torley, president and chief executive officer. "This new work continues to demonstrate the potential ability of PEGPH20 to increase tumor growth inhibition and the accumulation of co-administered therapies across a range of tumor types. We are also excited to share the first details of two pipeline assets that we believe hold great promise for the future."

Dr. Torley and Halozyme Chief Scientific Officer, Dr. Michael LaBarre will host a meeting for investment professionals during the AACR conference to review data included in the abstracts. The meeting will take place on Monday, April 18 at 4 p.m. ET (3 p.m. CT, 1 p.m. PT). The event will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the event.

To access the webcast and additional documents related to the event, please visit www.halozyme.com approximately fifteen minutes prior to the start time to register, download and install any necessary audio software. The live event may be accessed by calling (877) 410-5657 (domestic callers) or (334) 323-7224 (international callers) using passcode 987221. A telephone replay will be available after the event by dialing (877) 919-4059 (domestic callers) or (334) 323-0140 (international callers) using replay passcode 13259083.

Halozyme's AACR abstracts include:

  1. PEGylated recombinant hyaluronidase PH20 enhances pemetrexed antitumor efficacy in a human non-small cell lung cancer model, Sun., April 17, 1-5 p.m. CT
  2. Preclinical evaluation of a next-generation EGFR targeting antibody-drug conjugate that promotes regression in KRAS and BRAF tumors, Mon., April 18, 8 a.m.noon CT
  3. Enzymatic depletion of adenosine by PEGylated, engineered adenosine deaminase 2 (PEG-ADA2): a novel immunotherapeutic approach to treat solid tumors, Mon., April 18, 8 a.m.noon CT
  4. PEGPH20 increases the anticancer activity of standard chemotherapy combinations, vincristine (VIN) and D actinomycin (DACT), in a Wilms xenograft model, Mon., April 18, 1-5 p.m. CT
  5. PEGylated recombinant hyaluronidase PH20 (PEGPH20) enhances checkpoint inhibitor efficacy in syngeneic mouse models of cancer, Weds., April 20, 8 a.m.noon CT

About PEGPH20
PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under clinical development for the potential systemic treatment of tumors that accumulate hyaluronan. FDA granted orphan drug designation to PEGPH20 for treatment of pancreatic cancer and fast track for PEGPH20 in combination with gemcitabine and nab-paclitaxel for the treatment of metastatic pancreatic cancer.

Additionally, the European Commission, acting on the recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency, designated investigational drug PEGPH20 an orphan medicinal product for the treatment of pancreatic cancer.

About Halozyme
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme's lead proprietary program, investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor in animal models. PEGPH20 is currently in development for metastatic pancreatic cancer, non-small cell lung cancer, gastric cancer, metastatic breast cancer and has potential across additional cancers in combination with different types of cancer therapies. In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Baxalta, Pfizer, Janssen, AbbVie and Lilly for its ENHANZE™ drug delivery platform. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.

Safe Harbor Statement 
In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning the possible activity, benefits and attributes of PEGPH20, the possible method of action of PEGPH20, its potential application to improve cancer therapies and statements concerning future actions and clinical trials relating to the development of PEGPH20) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected expenditures and costs, unexpected results or delays in development and regulatory review, regulatory approval requirements, unexpected adverse events and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the Company's Annual Report on Form 10-K recently filed with the Securities and Exchange Commission.

Jim Mazzola

Chris Burton

Halozyme Therapeutics, Inc. Logo.

Logo - http://photos.prnewswire.com/prnh/20100302/LA63139LOGO


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/halozyme-to-present-data-from-five-preclinical-studies-at-american-association-of-cancer-research-annual-conference-300237488.html

SOURCE Halozyme Therapeutics, Inc.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.